ReviewFrontiers in immunology2026
Framework-mediated binding of foreign and self-glycans by IGHV4-34 antibodies.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cold agglutinin disease is an autoimmune condition characterised by expression of self-reactive antibodies to I/i carbohydrate blood group antigens (polymers of N-acetyllactosamine or 'LacNAc' units) resulting in anaemia through the agglutination and complement-mediated destruction of red blood cells. This antibody response is dominated by antibodies of the human IGHV4-34 germline, which display a unique hydrophobic patch formed by germline-encoded tryptophan and tyrosine residues at positions 7 and 25 within framework 1 (FR1). Although the requirement for conservation of this FR1 patch for binding to the I/i carbohydrate antigen has been well established, structural insights regarding the mechanistic role of the FR1 patch have remained elusive. Intriguingly, recent papers describing IGHV4-34 antibodies bound to the glycan-adorned surface of the HIV envelope glycoprotein shed light on the utility of this FR1 surface. Rather than indirectly shaping the conformation of the conventional antigen binding site as previously proposed, the structures reveal direct interfaces between the hydrophobic FR1 patch and high mannose glycans projected by HIV. Given the stereochemical similarities between these glycans and LacNAc, these structures suggest how I/i self-antigen glycans might be similarly engaged by IGHV4-34 antibodies in a framework-centric non-CDR mode and provide a rationale for the preservation of this otherwise self-reactive antibody germline.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.